Veradigm Inc. (MDRX)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Veradigm Inc. (MDRX) trades at $4.58 with AI Score 50/100 (Hold). Veradigm Inc. provides healthcare information technology solutions, including practice management software, electronic health records, and revenue cycle management. Market cap: $777.82M, Sector: Healthcare.
Last analyzed: Mar 15, 2026Veradigm Inc. (MDRX) Healthcare & Pipeline Overview
Veradigm Inc. delivers healthcare technology solutions, encompassing practice management, electronic health records, and revenue cycle management. Catering to providers, payers, and biopharma, Veradigm operates in a competitive healthcare IT landscape, focusing on data-driven insights and connectivity to improve healthcare outcomes and efficiency.
Investment Thesis
Veradigm Inc. presents a complex investment thesis. The company's diverse product portfolio, serving various healthcare segments, offers revenue diversification. Growth catalysts include expanding real-world data solutions for biopharma and increasing adoption of its payer solutions. However, the company's negative P/E ratio of -7.22 and negative profit margin of -14.7% raise concerns about profitability. The company's market capitalization stands at $0.82 billion as of 2026-03-15. Successful execution of its strategic initiatives and a return to profitability are critical for long-term value creation. Investors should carefully weigh the growth opportunities against the financial risks.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.82 billion reflects its position in the healthcare technology market.
- Negative P/E ratio of -7.22 indicates current challenges in profitability.
- Gross margin of 52.5% suggests a strong pricing power in its core offerings.
- Beta of 0.55 indicates lower volatility compared to the overall market.
- No dividend yield reflects a focus on reinvesting earnings for growth.
Competitors & Peers
Strengths
- Comprehensive suite of healthcare IT solutions.
- Established customer base across healthcare providers, payers, and biopharma.
- Strong data analytics capabilities.
- Experienced management team.
Weaknesses
- Negative profitability and P/E ratio.
- High debt levels.
- Dependence on key customers.
- Exposure to regulatory changes.
Catalysts
- Upcoming: Expansion of real-world data solutions for biopharma companies, driving revenue growth.
- Ongoing: Increased adoption of payer solutions, leading to higher subscription revenue.
- Ongoing: Strategic partnerships and acquisitions to expand product portfolio and market reach.
- Ongoing: Continuous improvement of EHR and practice management systems to attract new customers.
- Ongoing: International expansion to tap into new markets and diversify revenue streams.
Risks
- Potential: Intense competition in the healthcare IT market could erode market share.
- Potential: Cybersecurity risks and data breaches could damage reputation and lead to financial losses.
- Potential: Economic downturn and reduced healthcare spending could negatively impact revenue.
- Potential: Changes in healthcare regulations could create compliance challenges and increase costs.
- Ongoing: Negative profitability and P/E ratio raise concerns about financial sustainability.
Growth Opportunities
- Expansion of Real-World Data (RWD) Solutions: Veradigm can capitalize on the increasing demand for real-world data in the biopharmaceutical industry. The market for RWD and real-world evidence (RWE) is projected to reach billions of dollars by 2030. Veradigm's existing data sets and analytics platform provide a strong foundation for growth in this area. Timeline: Ongoing.
- Adoption of Payer Solutions: Veradigm's solutions for health plans and payers, including risk adjustment analytics and quality management tools, offer significant growth potential. As payers increasingly focus on value-based care and population health management, the demand for these solutions will continue to rise. Timeline: Ongoing.
- Enhancement of EHR and Practice Management Systems: Veradigm can drive growth by continuously improving its electronic health record (EHR) and practice management systems. By incorporating AI and automation, Veradigm can enhance the efficiency and usability of these systems, attracting new customers and retaining existing ones. Timeline: Ongoing.
- Strategic Partnerships and Acquisitions: Veradigm can pursue strategic partnerships and acquisitions to expand its product portfolio and market reach. By partnering with complementary technology providers or acquiring companies with innovative solutions, Veradigm can accelerate its growth and strengthen its competitive position. Timeline: Ongoing.
- International Expansion: Veradigm has the opportunity to expand its presence in international markets. By adapting its solutions to meet the specific needs of different countries, Veradigm can tap into new sources of revenue and diversify its geographic footprint. Timeline: Ongoing.
Opportunities
- Expansion of real-world data solutions.
- Increased adoption of payer solutions.
- Strategic partnerships and acquisitions.
- International expansion.
Threats
- Intense competition in the healthcare IT market.
- Cybersecurity risks and data breaches.
- Economic downturn and reduced healthcare spending.
- Changes in healthcare regulations.
Competitive Advantages
- Switching Costs: High switching costs for healthcare providers who have integrated Veradigm's software into their workflows.
- Data Network Effects: The value of Veradigm's data analytics solutions increases as more data is collected and analyzed.
- Regulatory Expertise: Deep understanding of healthcare regulations and compliance requirements.
- Established Customer Base: Long-standing relationships with a large base of healthcare providers and payers.
About MDRX
Founded in 1986 and headquartered in Chicago, Illinois, Veradigm Inc., formerly known as Allscripts Healthcare Solutions, Inc., is a healthcare technology company that provides information technology solutions to healthcare providers, payers, and biopharma companies both in the United States and internationally. The company's comprehensive suite of solutions includes Practice Management software, AI Patient Scheduling Software, Electronic Statements and Payments, Revenue Cycle Services, and electronic health records (EHR) solutions like ePrescribe with EPCS, Veradigm HER, and Practice Fusion HER. Veradigm also offers a Patient Engagement Platform to enhance patient-provider communication and care coordination. Veradigm's solutions extend to network partners through API connectivity solutions such as Veradigm Connect, Veradigm App Expo, and Diagnostic Ordering and Resulting Network. For health plans and payers, Veradigm provides risk adjustment solutions, quality management tools, data exchange, and provider engagement platforms. The company also serves the biopharma sector with real-world data solutions, real-world evidence analytics, and therapy-focused data sets. This broad portfolio positions Veradigm as a key player in the healthcare IT ecosystem, driving innovation and efficiency across various segments of the industry.
What They Do
- Provides Practice Management software to healthcare providers.
- Offers AI-powered Patient Scheduling Software.
- Facilitates Electronic Statements and Payments.
- Delivers Revenue Cycle Management solutions.
- Offers electronic health records (EHR) solutions.
- Provides a Patient Engagement Platform.
- Offers API connectivity solutions for network partners.
- Provides real-world data solutions to biopharma companies.
Business Model
- Software as a Service (SaaS): Generates recurring revenue through subscription fees for its software solutions.
- Data Analytics: Provides data analytics services to healthcare providers, payers, and biopharma companies.
- Transaction Fees: Charges transaction fees for services such as electronic claims processing and payment processing.
- Professional Services: Offers consulting and implementation services to help clients implement and optimize its solutions.
Industry Context
Veradigm Inc. operates within the rapidly evolving healthcare information technology sector. The industry is driven by increasing demand for digital health solutions, data analytics, and interoperability to improve patient outcomes and reduce costs. The competitive landscape includes companies like ARRJF (Allied Research Corp), ELEAF (Eleaf Co Ltd), INRLF (Interroll Holding AG), LFTSF (Lift Solutions AS), and PHCI (PHC Holdings Corp), each offering various specialized solutions. Veradigm's comprehensive suite of offerings positions it to capitalize on the growing demand for integrated healthcare technology solutions. The industry is expected to continue growing, driven by regulatory mandates, technological advancements, and the increasing need for efficient healthcare delivery.
Key Customers
- Healthcare Providers: Doctors, clinics, and hospitals that use Veradigm's software to manage their practices and patient data.
- Health Plans and Payers: Insurance companies and other organizations that pay for healthcare services.
- Biopharmaceutical Companies: Companies that develop and manufacture drugs and medical devices.
Financials
Chart & Info
Veradigm Inc. (MDRX) stock price: $4.58 (-0.03, -0.54%)
Latest News
-
Earnings Scheduled For August 4, 2022
benzinga · Aug 4, 2022
-
Stocks That Hit 52-Week Highs On Thursday
· Jan 7, 2021
-
Stocks That Hit 52-Week Lows On Monday
· Mar 16, 2020
-
Stocks That Hit 52-Week Lows On Friday
· Feb 28, 2020
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MDRX.
Price Targets
Wall Street price target analysis for MDRX.
MoonshotScore
What does this score mean?
The MoonshotScore rates MDRX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Donald D. Trigg
CEO
Donald D. Trigg serves as the CEO of Veradigm Inc. His background includes extensive experience in healthcare technology and leadership roles. Prior to Veradigm, Trigg held key positions at Cerner Corporation, where he focused on strategic growth initiatives and client relationship management. He has a proven track record of driving innovation and delivering value to healthcare organizations. Trigg's expertise spans across various aspects of healthcare IT, including electronic health records, data analytics, and population health management. His leadership is focused on transforming healthcare through technology and data-driven insights.
Track Record: Under Donald Trigg's leadership, Veradigm has focused on expanding its real-world data solutions and strengthening its partnerships with healthcare providers and payers. He has overseen the company's transition to a more data-driven and customer-centric approach. Key milestones include the launch of new analytics platforms and the expansion of Veradigm's presence in key markets. Trigg's strategic decisions have aimed to position Veradigm as a leading provider of healthcare technology solutions.
MDRX OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Veradigm Inc. may not meet the minimum financial standards required for listing on higher tiers like OTCQX or OTCQB, or on major exchanges like the NYSE or NASDAQ. Companies on this tier may have limited financial disclosure and may not be subject to the same regulatory oversight as exchange-listed companies. Investing in companies on the OTC Other tier carries higher risks due to the potential for less transparency and liquidity. This tier is often populated by shell companies, bankrupt entities, or companies with regulatory issues.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Financial Disclosure: Lack of transparency due to minimal reporting requirements.
- Low Liquidity: Difficulty in buying or selling shares due to low trading volume.
- Price Volatility: Higher price swings due to limited trading activity and market sentiment.
- Potential for Fraud: Increased risk of fraudulent activity due to less regulatory oversight.
- Delisting Risk: Possibility of being delisted from the OTC market due to non-compliance.
- Verify the company's financial statements and SEC filings (if any).
- Check the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Review any legal or regulatory issues facing the company.
- Evaluate the company's capital structure and debt levels.
- Monitor trading volume and price activity.
- Consult with a financial advisor before investing.
- Established Business Operations: Veradigm has been operating since 1986.
- Industry Presence: Veradigm is a known player in the healthcare technology sector.
- Employee Count: The company employs approximately 2450 people.
- Customer Base: Veradigm serves a diverse customer base across healthcare providers, payers, and biopharma.
What Investors Ask About Veradigm Inc. (MDRX)
What does Veradigm Inc. do?
Veradigm Inc. is a healthcare technology company that offers a range of solutions to healthcare providers, payers, and biopharma companies. Its core offerings include practice management software, electronic health records (EHR) systems, revenue cycle management tools, and data analytics services. The company's solutions help healthcare organizations improve efficiency, enhance patient care, and optimize financial performance. Veradigm operates in a competitive healthcare IT market, focusing on delivering integrated and data-driven solutions to its clients.
What do analysts say about MDRX stock?
Analyst consensus on MDRX stock is pending updated stock data. Key valuation metrics, such as the negative P/E ratio of -7.22, reflect current profitability challenges. Growth considerations include the company's expansion into real-world data solutions and its focus on payer solutions. Investors should carefully evaluate the company's financial performance and growth prospects before making investment decisions. Analyst ratings and price targets may vary, reflecting different perspectives on the company's potential.
What are the main risks for MDRX?
The main risks for Veradigm Inc. include intense competition in the healthcare IT market, cybersecurity threats, and potential changes in healthcare regulations. The company's negative profitability and high debt levels also pose financial risks. Additionally, Veradigm's dependence on key customers and exposure to economic downturns could negatively impact its revenue and earnings. Investors should carefully consider these risks before investing in MDRX.
What are the key factors to evaluate for MDRX?
Veradigm Inc. (MDRX) currently holds an AI score of 50/100, indicating moderate score. Key strength: Comprehensive suite of healthcare IT solutions.. Primary risk to monitor: Potential: Intense competition in the healthcare IT market could erode market share.. This is not financial advice.
How frequently does MDRX data refresh on this page?
MDRX prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven MDRX's recent stock price performance?
Recent price movement in Veradigm Inc. (MDRX) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Comprehensive suite of healthcare IT solutions.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider MDRX overvalued or undervalued right now?
Determining whether Veradigm Inc. (MDRX) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying MDRX?
Before investing in Veradigm Inc. (MDRX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- Analyst consensus is pending updated stock data.
- OTC market data may be limited and less reliable than exchange-listed data.